Literature DB >> 26272771

Bevacizumab: no comeback in early breast cancer?

Rupert Bartsch1, Michael Gnant2, Guenther G Steger3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26272771     DOI： 10.1016/S1470-2045(15)00124-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer.

Authors:  Florence T H Wu; Marta Paez-Ribes; Ping Xu; Shan Man; Elena Bogdanovic; Gavin Thurston; Robert S Kerbel
Journal:  Sci Rep       Date:  2016-11-14       Impact factor: 4.379

2.  A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition.

Authors:  Valentina Labanca; Francesco Bertolini
Journal:  EBioMedicine       Date:  2016-08-02       Impact factor: 8.143
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.